Boron-containing compounds (BCC) have emerged as important pharmacophores. To date,
five BCC drugs (including boronic acids and boroles) have been approved by the FDA for …

Resistance to β-lactam antibiotics is rapidly growing, substantially due to the spread of
serine-β-lactamases (SBLs) and metallo-β-lactamases (MBLs), which efficiently catalyse β …

Infections caused by resistant bacteria are nowadays too common, and some pathogens
have even become resistant to multiple types of antibiotics, in which case few or even no …

Carbapenem resistance is a major global health problem that seriously compromises the
treatment of infections caused by nosocomial pathogens. Resistance to carbapenems …

β-lactam antibiotics (BLAs) are crucial molecules among antibacterial drugs, but the
increasing emergence of resistance to them, developed by bacteria producing β-lactamase …

Computationally driven engineering of proteins aims to allow them to withstand an extended
range of conditions and to mediate modified or novel functions. Therefore, it is crucial to the …

Metallo-β-lactamases (MBLs) contribute to the resistance of Gram-negative bacteria to
carbapenems, last-resort antibiotics at hospital, and MBL inhibitors are urgently needed to …

The effectiveness of β-lactam antibiotics is increasingly influenced by serine β-lactamases
(SBLs) and metallo-β-lactamases (MBLs), which can hydrolyze β-lactam antibiotics. The …

Resistance to β‐lactam antibacterials is commonly associated with the production of the
serine β‐lactamases (SBLs) and/or metallo‐β‐lactamases (MBLs). Although clinically useful …

Serine/metallo-carbapenemase-coproducing pathogens, often referred to as “superbugs”,
are a significant clinical problem. They hydrolyze nearly all available β-lactam antibiotics …